May 5, 2026 · Menopause (New York, N.Y.) · DOI: 10.1097/GME.0000000000002768

Report of the FDA's expert panel on hormone therapy

Listen to this summary

The FDA's expert panel convened to evaluate the benefits and risks of menopausal hormone therapy, focusing on the distinctions between systemic and local vaginal estrogen, as well as the implications of class labeling and boxed warnings. The panel aimed to clarify the risk profiles associated with different estrogen and progestogen combinations and emphasized the importance of formulation and administration methods. Ultimately, the panel's discussions led to a recommendation for the FDA to consider removing boxed warnings from estrogen therapies, reflecting a nuanced understanding of their use in menopausal care.

JoAnn V Pinkerton, James A Simon, Howard N Hodis, Mary Jane Minkin, JoAnn E Manson, Barbara Levy

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play